Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

10. Subsequent Events

On July 5, 2017, the exclusive license granted by the Company to Novartis for the global development and commercialization of emricasan became effective under the terms of the Collaboration Agreement. The license became effective upon the Company’s receipt of a $7.0 million option exercise payment from Novartis pursuant to the Collaboration Agreement, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.